Although the majority of breast cancers are ER-positive and approximately 25–30% are ER-negative, current chemotherapeutic strategies for breast cancer treatment commonly rely on the expression of important biomarkers such as estrogen receptor (ER), progesterone receptor (PGR) and HER2 protein [2,3]. This evidence concerns the gene ERBB2 and breast carcinoma.